BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Estimates By $0.27 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.27, Briefing.com reports. The firm had revenue of $145.53 million during the quarter, compared to the consensus estimate of $126.83 million. The firm's quarterly revenue was up 56.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.17) earnings per share.

BioCryst Pharmaceuticals Trading Down 1.9 %

BioCryst Pharmaceuticals stock traded down $0.19 during midday trading on Wednesday, hitting $10.08. 7,304,265 shares of the stock were exchanged, compared to its average volume of 2,949,481. The stock's 50-day simple moving average is $7.81 and its 200 day simple moving average is $7.86. BioCryst Pharmaceuticals has a fifty-two week low of $5.04 and a fifty-two week high of $11.11. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -16.52 and a beta of 1.08.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. Needham & Company LLC lifted their price target on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective for the company. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $13.00 target price (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.